Press release
Acinetobacter Infections Pipeline Expands as 7+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Omnix Medical, Roche, Telum Therapeutics, Spero Therapeutics
Acinetobacter Infections - Pipeline Insight, 2026
DelveInsight's "Acinetobacter Infections - Pipeline Insight, 2026" report provides comprehensive insights about 8+ companies developing 10+ pipeline drugs in the Acinetobacter Infections pipeline landscape. It covers the Acinetobacter Infections pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Acinetobacter Infections treatment landscape. Learn more about the evolving Acinetobacter Infections pipeline today @ https://www.delveinsight.com/report-store/acinetobacter-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Acinetobacter Infections Pipeline Report
*
In July 2025, Brii Biosciences licensed BRII-693 (targeting Acinetobacter baumannii and Pseudomonas infections) to Joincare Group for exclusive development and commercialization in Greater China.
*
In April 2025, Shionogi signed an exclusive licensing agreement with Link Healthcare for cefiderocol development and commercialization in Australia and New Zealand, targeting Acinetobacter-resistant infections.
*
The leading Acinetobacter infections companies include Omnix Medical, Roche, Telum Therapeutics, Spero Therapeutics, VenatoRx Pharmaceuticals, ABAC Therapeutics, and others are evaluating their lead assets to improve the Acinetobacter infections treatment landscape.
*
Key Acinetobacter infection pipeline therapies in various stages of development include OMN6, RG6006, SPR-206, Research programme: PBP inhibitor program, and others.
Download for updates and the latest revolution in Acinetobacter Infections care @ Acinetobacter Infections Clinical Trials Assessment [https://www.delveinsight.com/sample-request/acinetobacter-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Acinetobacter Infections Emerging Drugs Profile
*
OMN6: Omnix Medical Ltd
OMN6 is a novel, first-in-class antimicrobial peptide (AMP) based on insect host defense peptides. Its mechanism of action (MoA) is based on disruption of bacterial cell membranes and is therefore effective regardless of bacterial genotype or resistance phenotype, and unlike conventional bacteriostatic antibiotics, it is fast acting and bactericidal. The US Food and Drug Administration (FDA) has also granted fast-track designation to OMN6. Currently, the drug is in Phase II stage of its development for the treatment of Acinetobacter Infections.
*
BV100: Bioversys
BV100 has a novel mode of action addressing carbapenem resistant Acinetobacter baumannii (CRAB) lung and blood stream infections. Currently, the drug is in Phase II stage of its development for the treatment of Acinetobacter Infections.
*
MRX-8: MicuRx
MRX-8 is a next-generation polymyxin antibiotic developed by MicuRx to target multidrug-resistant Gram-negative bacteria, including carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and other resistant pathogens. Currently, the drug is in Phase I stage of its development for the treatment of Acinetobacter Infections.
For more information on the Acinetobacter Infections Emerging Drugs Profile, download DelveInsight's comprehensive Acinetobacter Infections Pipeline Insight report [https://www.delveinsight.com/sample-request/acinetobacter-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Acinetobacter Infections Pipeline Report Provides
*
Detailed insights about companies developing therapies for Acinetobacter Infections, with aggregate therapies developed by each company.
*
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Acinetobacter Infections treatment.
*
Acinetobacter Infections companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Acinetobacter Infections drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Acinetobacter Infections market.
Learn more about Acinetobacter Infections Drugs opportunities in our comprehensive Acinetobacter Infections pipeline report @ Acinetobacter Infections Unmet Needs [https://www.delveinsight.com/sample-request/acinetobacter-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Acinetobacter Infections Companies
There are 7+ key companies, such as Omnix Medical, Roche, Telum Therapeutics, Spero Therapeutics, VenatoRx Pharmaceuticals, ABAC Therapeutics, and others, developing therapies for Acinetobacter Infections.
DelveInsight's Acinetobacter Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
*
Oral
*
Intravenous
*
Subcutaneous
*
Parenteral
*
Topical
Acinetobacter Infections products have been categorized under various Molecule types such as:
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Discover the latest advancements in Acinetobacter Infections treatment by visiting our website. Stay informed @ Acinetobacter Infections Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/acinetobacter-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Scope of the Acinetobacter Infections Pipeline Report
*
Coverage: Global
*
Acinetobacter Infections companies: Omnix Medical, Roche, Telum Therapeutics, Spero Therapeutics, VenatoRx Pharmaceuticals, ABAC Therapeutics, and others.
*
Acinetobacter Infections Therapies: OMN6, RG6006, SPR-206, Research programme: PBP inhibitor program, and others.
*
Acinetobacter Infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
*
Acinetobacter Infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Table of Contents
*
Introduction
*
Executive Summary
*
Acinetobacter Infections: Overview
*
Pipeline Therapeutics
*
Therapeutic Assessment
*
Acinetobacter Infections - DelveInsight's Analytical Perspective
*
Late Stage Products (Phase III)
*
Mid Stage Products (Phase II)
*
Early Stage Products (Phase I)
*
Preclinical and Discovery Stage Products
*
Inactive Products
*
Acinetobacter Infections Key Companies
*
Acinetobacter Infections Key Products
*
Acinetobacter Infections Unmet Needs
*
Acinetobacter Infections Market Drivers and Barriers
*
Acinetobacter Infections Future Perspectives and Conclusion
*
Acinetobacter Infections Analyst Views
*
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acinetobacter-infections-pipeline-expands-as-7-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight-omnix-medical-roche-telum-therapeutics-spero-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acinetobacter Infections Pipeline Expands as 7+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Omnix Medical, Roche, Telum Therapeutics, Spero Therapeutics here
News-ID: 4394586 • Views: …
More Releases from ABNewswire
February Career Reset: Skilled Trades Offer Stability Beyond the Office Model
February is a time to reconsider career goals and seek real stability. Florida International Training Institute offers HVAC training Miami, air conditioning course programs, electrician certification training Miami, and plumbing school options. Through hands-on skills, electrical course in Miami and plumber course pathways prepare students for essential trades with constant demand.
As the momentum of January resolutions begins to settle, February often becomes a month of honest reflection. Many individuals start…
Metastatic Prostate Cancer Clinical Trial Pipeline Advances as 80+ Companies Dev …
DelveInsight's "Metastatic Prostate Cancer - Pipeline Insight, 2026" report provides comprehensive insights about 80+ companies including AstraZeneca, Arvinas, Daiichi Sankyo, Bristol Myers Squibb, Merck, MacroGenics, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, AB Science, Eli Lilly, Exelixis, Novartis, and Sanofi among others, developing 85+ pipeline drugs in the metastatic prostate cancer (mPC) pipeline landscape
DelveInsight's "Metastatic Prostate Cancer - Pipeline Insight, 2026" report provides comprehensive insights…
Living Water Resorts Joins GNEX 2026 as Gold Sponsor
Waterfront Resort Leader Supports Industry-Shaping Event in Nashville
Orlando, Fla. - February 17, 2026 - The Perspective Group and GNEX (Growth Networking EXperience) Conference today announced that Living Water Resorts, the only resort destination located on the shores of Georgian Bay in the heart of Collingwood, Ontario, will join GNEX 2026 as a Gold Sponsor. The event will take place March 18-20, 2026, at the JW Marriott in downtown Nashville, Tennessee.
As…
MAHA Uncensored: As RFK Jr.'s "Eat Real Food" Movement Captures National Attenti …
Salt Lake City, Utah - As Robert F. Kennedy Jr.'s Make America Healthy Again (MAHA) movement continues to dominate national headlines - from the widely discussed "Eat Real Food" Super Bowl advocacy campaign to renewed scrutiny of ultra-processed food policy and federal regulatory oversight - a powerful new documentary is set to expand the national conversation.
MAHA Uncensored, directed by award-winning filmmaker Jeff Hays ( The Real Anthony Fauci , On…
More Releases for Acinetobacter
Acinetobacter Pneumonia Therapeutics Market Exclusive Report with Detailed Study …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporins, Carbapenems, Aminoglycosides, Polymyxins), By Route of Administration (Oral, Intravenous, Others), Region, Market Outlook And Industry Analysis 2034"
The global Acinetobacter Pneumonia Therapeutics Market Size is valued at USD 646.05 Mn in 2024 and is predicted to reach USD 1101.68 Mn by the…
United States Acinetobacter Infections Treatment Market 2025 Outlook: Breakthrou …
The Global Acinetobacter Infections Treatment Market is estimated to reach at a significant CAGR during the forecasted period 2024-2031.
Acinetobacter infections treatment targets multidrug-resistant bacteria, primarily Acinetobacter baumannii, a major hospital-acquired pathogen. Therapeutic options include carbapenems, polymyxins, tigecycline, and combination antibiotic therapies. Due to rising resistance, novel treatments like bacteriophage therapy and antimicrobial peptides are under study. Strict infection control measures are crucial to prevent spread in healthcare settings. Rapid diagnostics…
Acinetobacter Pneumonia Therapeutics Market Revenue Report with Forecast to 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporins, Carbapenems, Aminoglycosides, Polymyxins), By Route of Administration (Oral, Intravenous, Others), Region, Market Outlook And Industry Analysis 2034"
The global Acinetobacter Pneumonia Therapeutics Market Size is valued at USD 646.05 Mn in 2024 and is predicted to reach USD 1101.68 Mn by the…
Global Acinetobacter Infections Treatment Market Research Report 2020
LOS ANGELES - USA, Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or "species" of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly…
Acinetobacter Infections Treatment Market with Worldwide Industry Analysis to 20 …
Global Acinetobacter Infections Treatment Market: Overview
Acinetobacter baumannii is a rod shaped gram-negative coccobacillus bacterium. This bacterium is becoming an important cause of hospital derived bacterial infection affecting people with weakened immune system. Acinetobacter infections usually affect organ systems, which have a high content of fluid (e.g. peritoneal fluid, respiratory tract, urinary tract, cerebrospinal fluid etc.) leading to infections related to continuous ambulatory peritoneal dialysis and nocosomial pneumonia. At present,…
Acinetobacter Infections - Pipeline Review, H1 2017 - Pharmaceutical Market Repo …
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H1 2017, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.
Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas…
